{"entity":{"id":"bbi-940","kind":"drug","name":"BBI-940","aka":[],"tldr":"BBI-940 is an oral small-molecule degrader from Boundless Bio that reached phase 1 for ER-positive/HER2-negative breast cancer and luminal androgen receptor triple-negative breast cancer; development has stopped.","summary":"BBI-940 is an oral small-molecule degrader from Boundless Bio. An oral selective degrader of a previously undrugged kinesin involved in DNA segregation, including segregation of extrachromosomal DNA (ecDNA) during cell division. Its furthest stage is phase 1, for ER-positive/HER2-negative breast cancer and luminal androgen receptor triple-negative breast cancer. ClinicalTrials.gov registers it in one study linked below. June 2026: company said early pharmacokinetic exposure in KOMODO-1 (human oral bioavailability well below preclinical prediction) did not support continued development (10-Q for quarter ended 30 June 2026). Registry trial NCT07408089 TERMINATED for a business decision related to a corporate transaction, not safety. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Boundless Bio: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/0001782303/000119312526339093/bold-20260630.htm"},{"label":"Boundless Bio: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/0001782303/000119312526339093/bold-20260630.htm"},{"label":"Boundless Bio: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07408089"},{"label":"ClinicalTrials.gov: trials of BBI-940","url":"https://clinicaltrials.gov/search?intr=BBI-940"}],"tags":["pipeline","ctgov-ingest","discontinued"],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["boundless-bio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07408089"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BBI-940","modality":"Oral small-molecule degrader","mechanism":"An oral selective degrader of a previously undrugged kinesin involved in DNA segregation, including segregation of extrachromosomal DNA (ecDNA) during cell division.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bbi-940/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"company":[{"id":"boundless-bio","kind":"company","name":"Boundless Bio","route":"/companies/boundless-bio/"}],"trial":[{"id":"nct07408089","kind":"trial","name":"Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer","route":"/trials/nct07408089/"}]}}